Preview

Современная ревматология

Расширенный поиск

Бисфосфонаты: приверженность терапии - залог успешного лечения остеопороза

https://doi.org/10.14412/1996-7012-2008-464

Полный текст:

Литература

1. <div><p>Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение» (ред. Л.И. Беневоленская, О.М. Лесняк). М.: ГЭОТАР-Медиа, 2005, 171 с.</p><p>Hochberg M.C., Greenspan S., Wasnich R.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87, 1586-92.</p><p>Беневоленская Л.И. Бисфосфонаты в терапии и профилактике остеопороза. Рос pевматол 1998; 2: 2-9.</p><p>Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.</p><p>Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643-58.</p><p>World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003.</p><p>Baroutsou B., Babiolakis D., Stamatiadou A. et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann Rheum Dis 2004; 63(suppl. 1): 455(SATO240).</p><p>Kendler D., Kung A.W., Fuleihan Gel H. et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243-51.</p><p>Simon J.A., Lewiecki E.M., Smith M.E. et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, cross-over study. Clin Ther 2002; 24: 1871-86.</p><p>Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bisphosphonate dosing regimens among women with post- menopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-60.</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis. Curr Med Res Opin 2005; 21: 1895-903.</p><p>Barrett J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharma-cokinetic update. J Clin Pharmacol 2004; 44: 951-65.</p><p>Bauss F., Russel R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporosis Int 2004; 15: 423-33.</p><p>Munbauers R.C., Bauss F., Schenk R. et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6: 1003-11.</p><p>Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariec- tomized aged rats. J Rheumatol 2002; 29: 990-98.</p><p>Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. Osteoporos Int 2000; 11(suppl.1): S26.</p><p>Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 1996; 6: 166-70.</p><p>Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties. J Bone Miner Res 1999; 14: 1768-78.</p><p>Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safety of oral weekly iban-dronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; V 88: P 4609 - 15.</p><p>Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 1871-8.</p><p>Reginster J.-Y., Wilson K.M., Dumount E. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. J Clin Endocrinol Metab 2005; 90: 5018-24.</p><p>Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in post-menopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-22.</p><p>Reginster J.-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis. Ann Rheum Dis 2006; 65:654-61.</p><p>Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.</p><p>Cranney A. Wells G., Adachi R. Non-vertebral fracture reduction with high- versus low-dose ibandronate: meta-analysis of individual patient data. Ann Rheum Dis 2007; 66(suppl. 2): 681.</p><p>Hadji P, Benhamou C.-L., Devas V. et al. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate results of Balto II. Abstr. Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Osteoporos Int 2006; 17 (Suppl. 1).</p><p>Cooper A., Drake J., Brankin E. et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60 (8): 896-905.</p></div><br />


Для цитирования:


Торопцова Н.В., Беневоленмкая Л.И., Торопцова Н.В., Беневоленмкая Л.И. Бисфосфонаты: приверженность терапии - залог успешного лечения остеопороза. Современная ревматология. 2008;2(1):78-81. https://doi.org/10.14412/1996-7012-2008-464

For citation:


Toroptsova N.V., Benevolenskaya L.I., Toroptsova N.V., Benevolenskaya L.I. Biophosphonates: adherence to therapy is a pledge of successful treatment for osteoporosis. Modern Rheumatology Journal. 2008;2(1):78-81. (In Russ.) https://doi.org/10.14412/1996-7012-2008-464

Просмотров: 680


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)